Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

JAVELIN Renal 101 trial: avelumab and axitinib for advanced renal cell carcinoma

Share :

ESMO 2018

19 - 23 Oct 2018
Published: 21 Oct 2018
Views: 2650
Rating:
Save
Dr Robert J. Motzer - Memorial Sloan-Kettering Cancer Center, New York, USA

Dr Robert J. Motzer speaks at the ESMO 2018 congress about avelumab axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma.

To watch his interview with ecancer click here.

Related Videos

EAU 2024: Bladder cancer latest
Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea...
EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )
9 Apr 2024
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )
25 Mar 2024
A biomarker led approach to bladder cancer
Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr...
A biomarker led approach to bladder cancer ( Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr Yohann Loriot )
22 Oct 2023
OncoAlert round up July 28th to August 3rd, 2023
Dr Gil Morgan - Executive Director, OncoAlert
OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )
4 Aug 2023
mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit...
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
5 Jun 2023
Erdafitinib and current treatment landscape for advanced bladder cancer
Dr Yohann Loriot and Prof Arlene Siefker-Radtke
Erdafitinib and current treatment landscape for advanced bladder cancer ( Dr Yohann Loriot and Prof Arlene Siefker-Radtke )
5 Jun 2023
The current status of multiple myeloma diagnosis and treatment
Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina
The current status of multiple myeloma diagnosis and treatment ( Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina )
24 May 2023
Four chemo cycles given with durvalumab and tremelimumab optimise response and...
Dr Niels Reinmuth - University of Muenster, Gauting, Germany
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC ( Dr Niels Reinmuth - University of Muenster, Gauting, Germany )
6 Apr 2023
CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG
Dr Roger Li - Moffitt Cancer Center, Tampa, USA
CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG ( Dr Roger Li - Moffitt Cancer Center, Tampa, USA )
22 Mar 2023

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation